Propionibacterium acnes Enhances the Immunogenicity of HIVBr18 Human Immunodeficiency Virus-1 Vaccine

Página do item simplificado
dc.citation.volume9
dc.contributor.authorTeixeira, Daniela [UNIFESP]
dc.contributor.authorIshimura, Mayari Eika [UNIFESP]
dc.contributor.authorApostolico, Juliana de Souza [UNIFESP]
dc.contributor.authorViel, Jacqueline Miyuki [UNIFESP]
dc.contributor.authorPassarelli, Victor Cabelho [UNIFESP]
dc.contributor.authorCunha-Neto, Edecio
dc.contributor.authorRosa, Daniela Santoro [UNIFESP]
dc.contributor.authorLongo-Maugeri, Ieda Maria [UNIFESP]
dc.coverageLausanne
dc.date.accessioned2020-07-08T13:09:41Z
dc.date.available2020-07-08T13:09:41Z
dc.date.issued2018
dc.description.abstractImmunization of BALB/c mice with HIVBr18, a DNA vaccine containing 18 CD4(+) T cell epitopes from human immunodeficiency virus (HIV), induced specific CD4(+) and CD8(+) T cell responses in a broad, polyfunctional and persistent manner. With the aim of increasing the immunogenicity of this vaccine, the effect of Propionibacterium acnes as an adjuvant was evaluated. The adjuvant effects of this bacterium have been extensively demonstrated in both experimental and clinical settings. Herein, administration of two doses of HIVBr18, in the presence of P. acnes, increased the proliferation of HIV-1-specific CD4(+) and CD8(+) T lymphocytes, the polyfunctional profile of CD4(+) T cells, the production of IFN-gamma, and the number of recognized vaccine-encoded peptides. One of the bacterial components responsible for most of the adjuvant effects observed was a soluble polysaccharide extracted from the P. acnes cell wall. Furthermore, within 10 weeks after immunization, the proliferation of specific T cells and production of IFN-gamma were maintained when the whole bacterium was administered, demonstrating a greater effect on the longevity of the immune response by P. acnes. Even with fewer immunization doses, P. acnes was found to be a potent adjuvant capable of potentiating the effects of the HIVBr18 vaccine. Therefore, P. acnes may be a potential adjuvant to aid this vaccine in inducing immunity or for therapeutic use.en
dc.description.affiliationUniv Fed Sao Paulo, Div Immunol, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil
dc.description.affiliationUniv Sao Paulo, Sch Med, Lab Clin Immunol & Allergy LIM60, Sao Paulo, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo
dc.description.sponsorshipConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
dc.description.sponsorshipIDFAPESP: 2014/25307-4
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.3389/fimmu.2018.00177
dc.identifier.citationFrontiers In Immunology. Lausanne, v. 9, p. -, 2018.
dc.identifier.doihttps://doi.org/10.3389/fimmu.2018.00177
dc.identifier.fileWOS000424353400001.pdf
dc.identifier.issn1664-3224
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/54137
dc.identifier.wosWOS:000424353400001
dc.language.isoeng
dc.publisherFrontiers Media Sa
dc.relation.ispartofFrontiers In Immunology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectPropionibacterium acnesen
dc.subjectadjuvanten
dc.subjecthuman immunodeficiency virus-1en
dc.subjectDNA vaccineen
dc.subjectCD4(+) T cellen
dc.subjectimmunomodulationen
dc.titlePropionibacterium acnes Enhances the Immunogenicity of HIVBr18 Human Immunodeficiency Virus-1 Vaccineen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
WOS000424353400001.pdf
Tamanho:
4.22 MB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos